The evidence brief
Peptide guides, graded honestly.
News on the FDA's peptide decisions, compound deep-dives, safety and legal explainers, and head-to-head comparisons. Every claim cited, every peptide graded A to F by human evidence.
News
The FDA Panel Backed 6 of 7 Peptides and Rejected DSIP. What It Means.
Across July 23 and 24, 2026 the FDA's advisory committee recommended six of the seven peptides it reviewed for the compounding list, overriding the agency's own scientists, and rejected Emideltide (DSIP). Every per-peptide tally, and the one thing most coverage gets wrong: this is a recommendation, not a legalization.
Jul 30, 20266 min read
News
The 7 Peptides the FDA Decides On This July (PCAC Preview)
On July 23 to 24, 2026 the FDA's advisory committee votes on whether seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon) can be legally compounded. What's at stake, and what the evidence really shows.
Jul 6, 20267 min read
Get the monthly peptide evidence brief.
What the research and the FDA actually say. One short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.